Cargando…

Neutralizing antibody 5-7 defines a distinct site of vulnerability in SARS-CoV-2 spike N-terminal domain

Antibodies that potently neutralize SARS-CoV-2 target mainly the receptor-binding domain or the N-terminal domain (NTD). Over a dozen potently neutralizing NTD-directed antibodies have been studied structurally, and all target a single antigenic supersite in NTD (site 1). Here, we report the cryo-EM...

Descripción completa

Detalles Bibliográficos
Autores principales: Cerutti, Gabriele, Guo, Yicheng, Wang, Pengfei, Nair, Manoj S., Wang, Maple, Huang, Yaoxing, Yu, Jian, Liu, Lihong, Katsamba, Phinikoula S., Bahna, Fabiana, Reddem, Eswar R., Kwong, Peter D., Ho, David D., Sheng, Zizhang, Shapiro, Lawrence
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8519878/
https://www.ncbi.nlm.nih.gov/pubmed/34706271
http://dx.doi.org/10.1016/j.celrep.2021.109928
_version_ 1784584546588557312
author Cerutti, Gabriele
Guo, Yicheng
Wang, Pengfei
Nair, Manoj S.
Wang, Maple
Huang, Yaoxing
Yu, Jian
Liu, Lihong
Katsamba, Phinikoula S.
Bahna, Fabiana
Reddem, Eswar R.
Kwong, Peter D.
Ho, David D.
Sheng, Zizhang
Shapiro, Lawrence
author_facet Cerutti, Gabriele
Guo, Yicheng
Wang, Pengfei
Nair, Manoj S.
Wang, Maple
Huang, Yaoxing
Yu, Jian
Liu, Lihong
Katsamba, Phinikoula S.
Bahna, Fabiana
Reddem, Eswar R.
Kwong, Peter D.
Ho, David D.
Sheng, Zizhang
Shapiro, Lawrence
author_sort Cerutti, Gabriele
collection PubMed
description Antibodies that potently neutralize SARS-CoV-2 target mainly the receptor-binding domain or the N-terminal domain (NTD). Over a dozen potently neutralizing NTD-directed antibodies have been studied structurally, and all target a single antigenic supersite in NTD (site 1). Here, we report the cryo-EM structure of a potent NTD-directed neutralizing antibody 5-7, which recognizes a site distinct from other potently neutralizing antibodies, inserting a binding loop into an exposed hydrophobic pocket between the two sheets of the NTD β sandwich. Interestingly, this pocket was previously identified as the binding site for hydrophobic molecules, including heme metabolites, but we observe that their presence does not substantially impede 5-7 recognition. Mirroring its distinctive binding, antibody 5-7 retains neutralization potency with many variants of concern (VOCs). Overall, we reveal that a hydrophobic pocket in NTD proposed for immune evasion can be used by the immune system for recognition.
format Online
Article
Text
id pubmed-8519878
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher The Author(s).
record_format MEDLINE/PubMed
spelling pubmed-85198782021-10-18 Neutralizing antibody 5-7 defines a distinct site of vulnerability in SARS-CoV-2 spike N-terminal domain Cerutti, Gabriele Guo, Yicheng Wang, Pengfei Nair, Manoj S. Wang, Maple Huang, Yaoxing Yu, Jian Liu, Lihong Katsamba, Phinikoula S. Bahna, Fabiana Reddem, Eswar R. Kwong, Peter D. Ho, David D. Sheng, Zizhang Shapiro, Lawrence Cell Rep Report Antibodies that potently neutralize SARS-CoV-2 target mainly the receptor-binding domain or the N-terminal domain (NTD). Over a dozen potently neutralizing NTD-directed antibodies have been studied structurally, and all target a single antigenic supersite in NTD (site 1). Here, we report the cryo-EM structure of a potent NTD-directed neutralizing antibody 5-7, which recognizes a site distinct from other potently neutralizing antibodies, inserting a binding loop into an exposed hydrophobic pocket between the two sheets of the NTD β sandwich. Interestingly, this pocket was previously identified as the binding site for hydrophobic molecules, including heme metabolites, but we observe that their presence does not substantially impede 5-7 recognition. Mirroring its distinctive binding, antibody 5-7 retains neutralization potency with many variants of concern (VOCs). Overall, we reveal that a hydrophobic pocket in NTD proposed for immune evasion can be used by the immune system for recognition. The Author(s). 2021-11-02 2021-10-16 /pmc/articles/PMC8519878/ /pubmed/34706271 http://dx.doi.org/10.1016/j.celrep.2021.109928 Text en © 2021 The Author(s) Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Report
Cerutti, Gabriele
Guo, Yicheng
Wang, Pengfei
Nair, Manoj S.
Wang, Maple
Huang, Yaoxing
Yu, Jian
Liu, Lihong
Katsamba, Phinikoula S.
Bahna, Fabiana
Reddem, Eswar R.
Kwong, Peter D.
Ho, David D.
Sheng, Zizhang
Shapiro, Lawrence
Neutralizing antibody 5-7 defines a distinct site of vulnerability in SARS-CoV-2 spike N-terminal domain
title Neutralizing antibody 5-7 defines a distinct site of vulnerability in SARS-CoV-2 spike N-terminal domain
title_full Neutralizing antibody 5-7 defines a distinct site of vulnerability in SARS-CoV-2 spike N-terminal domain
title_fullStr Neutralizing antibody 5-7 defines a distinct site of vulnerability in SARS-CoV-2 spike N-terminal domain
title_full_unstemmed Neutralizing antibody 5-7 defines a distinct site of vulnerability in SARS-CoV-2 spike N-terminal domain
title_short Neutralizing antibody 5-7 defines a distinct site of vulnerability in SARS-CoV-2 spike N-terminal domain
title_sort neutralizing antibody 5-7 defines a distinct site of vulnerability in sars-cov-2 spike n-terminal domain
topic Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8519878/
https://www.ncbi.nlm.nih.gov/pubmed/34706271
http://dx.doi.org/10.1016/j.celrep.2021.109928
work_keys_str_mv AT ceruttigabriele neutralizingantibody57definesadistinctsiteofvulnerabilityinsarscov2spikenterminaldomain
AT guoyicheng neutralizingantibody57definesadistinctsiteofvulnerabilityinsarscov2spikenterminaldomain
AT wangpengfei neutralizingantibody57definesadistinctsiteofvulnerabilityinsarscov2spikenterminaldomain
AT nairmanojs neutralizingantibody57definesadistinctsiteofvulnerabilityinsarscov2spikenterminaldomain
AT wangmaple neutralizingantibody57definesadistinctsiteofvulnerabilityinsarscov2spikenterminaldomain
AT huangyaoxing neutralizingantibody57definesadistinctsiteofvulnerabilityinsarscov2spikenterminaldomain
AT yujian neutralizingantibody57definesadistinctsiteofvulnerabilityinsarscov2spikenterminaldomain
AT liulihong neutralizingantibody57definesadistinctsiteofvulnerabilityinsarscov2spikenterminaldomain
AT katsambaphinikoulas neutralizingantibody57definesadistinctsiteofvulnerabilityinsarscov2spikenterminaldomain
AT bahnafabiana neutralizingantibody57definesadistinctsiteofvulnerabilityinsarscov2spikenterminaldomain
AT reddemeswarr neutralizingantibody57definesadistinctsiteofvulnerabilityinsarscov2spikenterminaldomain
AT kwongpeterd neutralizingantibody57definesadistinctsiteofvulnerabilityinsarscov2spikenterminaldomain
AT hodavidd neutralizingantibody57definesadistinctsiteofvulnerabilityinsarscov2spikenterminaldomain
AT shengzizhang neutralizingantibody57definesadistinctsiteofvulnerabilityinsarscov2spikenterminaldomain
AT shapirolawrence neutralizingantibody57definesadistinctsiteofvulnerabilityinsarscov2spikenterminaldomain